ASSOCIATION BETWEEN CARDIOMETABOLIC RISK FACTORS AND COVID-19 SUSCEPTIBILITY, SEVERITY AND MORTALITY: ASYSTEMATIC REVIEW
Keywords:
Cardiometabolic Risk, COVID-19, Mortality, SeverityAbstract
The most recent outbreak of the coronavirus has caused widespread devastation across all aspects of human existence and has accelerated the spread of the disease throughout the globe. The coronavirus illness that has been identified in 2019 (COVID-19) has been given the name 2019-nCOV. This unique virus is the cause of the COVID-19 disease, which exhibits signs and symptoms that are akin to those of severe acute respiratory syndrome coronavirus 2. (SARS-COV2). Cardiometabolic disease is a group of metabolic abnormalities that increase the risk of type 2 diabetes (T2DM) and cardiovascular diseases (CVDs). These metabolic abnormalities include insulin resistance, hyperglycemia, dyslipidemia, abdominal obesity, and hypertension (HTN). Environmental risk factors include smoking, leading a sedentary lifestyle, eating an unhealthy diet, and being poor. It is also possible to see it as a collection of interconnected pathophysiological abnormalities that take place in the cardiovascular system as well as other metabolic organs, which lead to an increased risk of type 2 diabetes and cardiovascular disease. According to the findings of study, persons who suffer from hypertension, diabetes mellitus type 2, and obesity are strongly associated with the susceptibility of the disease and the severity it manifests in COVID-19 patients. Although high blood pressure, also known as hypertension, is one of the most common cardiovascular comorbidities, it is not yet known whether or not the association between high blood pressure and COVID-19 is independent from advanced age.
References
He F; Deng Y; Li W; et al. Coronavirus disease 2019 (COVID-19): what we know? J Med Virol. 2020;
Guan WJ; Ni ZY; Hu Y; et al, Guan WJ, Ni ZY, Hu Y, et al, Guan WJ; Ni ZY; Hu Y; et al. Clinical characteristics of coronavirus disease 2019 in China. N Eng J Med. 2020;382(18):1708–20.
Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus – The species and its viruses, a statement of the Coronavirus Study Group. BioRxiv.
2020;2(7):93–7.
Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. April 2020;382(18):1708–20.
Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med. September 2020;17(9):e1003321.
Sinclair AJ, Abdelhafiz AH. Cardiometabolic disease in the older person: prediction and prevention for the generalist physician. Cardiovasc Endocrinol Metab. September 2020;9(3):90–5.
Hertle E, Stehouwer CDA, van Greevenbroek MMJ. The complement system in human cardiometabolic disease. Mol Immunol. Oktober 2014;61(2):135–48.
Ralston J, Nugent R. Toward a broader response to cardiometabolic disease. Nat Med. November 2019;25(11):1644–6.
Fauci AS, Jameson JL, Kasper D, et al. Harrison’s Principles of Internal Medicine 19th Edition. New York: McGraw-Hill Education; 2018.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). Maret 2020;395(10229):1054–62.
Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. Juli 2020;75(7):1730–41.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England). Februari 2020;395(10223):497–506.
Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. Mei 2020;323(18):1775–6.
Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. bmj.
2020;369.
Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22- May 30, 2020. MMWR Morb Mortal Wkly Rep. Juni 2020;69(24):759–65.
Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. Vol. 323, JAMA - Journal of the American Medical Association. American Medical Association; 2020. hal. 1239–42.
Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. Juli 2020;92(7):797–806.
Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li Y-M, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. Mei 2020;55(5).
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. Mei 2020;323(20):2052–9.
Ghoneim S, Butt MU, Hamid O, Shah A, Asaad I. The incidence of COVID-19 in patients with metabolic syndrome and non-alcoholic steatohepatitis: A population- based study. Metab open. Desember 2020;8:100057.
Yanai H. Significant Correlations of SARS-CoV-2 Infection With Prevalence of Overweight/Obesity and Mean Body Mass Index in the SARS-CoV-2 Endemic Countries. Cardiol Res. Desember 2020;11(6):412–4.
Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. SARS- CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. Oktober 2020;11(1):5493.
Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. Februari 2011;11(2):85–97.
Hotamisligil GS. Inflammation and metabolic disorders. Nature. Desember [27] 2006;444(7121):860–7.
Kulkarni S, Jenner BL, Wilkinson I. COVID-19 and hypertension. J Renin Angiotensin Aldosterone Syst. 2020;21(2):1470320320927851.
Perumareddi P. Prevention of hypertension related to cardiovascular disease. Prim Care Clin Off Pract. 2019;46(1):27–39.
Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. Maret 2020;94(7).
Rabaan AA, Al-Ahmed SH, Garout MA, Al-Qaaneh AM, Sule AA, Tirupathi R, et al. Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses. Pathog (Basel, Switzerland). Mei 2021;10(5).
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID- 19): A Review. JAMA [Internet] 25 Agustus 2020;324(8):782–
Tersedia pada: https://doi.org/10.1001/jama.2020.12839
Chua RL, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F, et al. COVID- 19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat Biotechnol. Agustus 2020;38(8):970–9.
Fara A, Mitrev Z, Rosalia RA, Assas BM. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biol. 2020;10(9):200160.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
